A new study published in Nature Communications reports the results of a phase II trial (NCT03274258) of combination immune checkpoint therapy (ICT) with nivolumab plus ipilimumab in patients with renal medullary carcinoma (RMC), together with mechanistic studies explaining the clinical results. Enrollment was halted early for futility: all 10 treated patients experienced rapid disease progression, 5 of 10 met radiologic criteria for hyperprogression, and median progression-free survival was only 1.38 months. Single-cell RNA sequencing of patient tumors before and after nivolumab plus ipilimumabt, together with experiments in an immunocompetent genetically engineered mouse model of RMC, revealed that ICT triggers an interferon-γ response that drives a “myeloid mimicry” transcriptional program in RMC tumor cells through the CEBPB/p300 axis, fueling proliferation and hyperprogression — and that selective pharmacologic inhibition of p300 suppresses this program and restores sensitivity to ICT. These findings provide strong clinical and mechanistic evidence that combination immune checkpoint inhibitors should not be used to treat RMC, and identify p300/CEBPB as a promising target to overcome this resistance in future combination strategies.